Onderneming Reshape Lifesciences Inc Nasdaq
Aandelen
US7611231082
Geavanceerde medische apparatuur & technologie
Vakgebied
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Minimally Invasive Medical Devices
100,0
%
| 11 | 100,0 % | 9 | 100,0 % | -22,79% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
82,2
%
| 9 | 82,1 % | 7 | 82,2 % | -22,71% |
Europe
11,0
%
| 1 | 11,1 % | 1 | 11,0 % | -23,64% |
Australia
6,1
%
| 1 | 6,1 % | 1 | 6,1 % | -23,55% |
Rest of World
0,7
%
| 0 | 0,6 % | 0 | 0,7 % | -11,43% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Paul Hickey
CEO | Chief Executive Officer | 59 | 01-02-20 |
Director of Finance/CFO | 63 | 15-06-21 | |
Dov Gal
CMP | Compliance Officer | - | - |
Al Diaz
COO | Chief Operating Officer | - | 31-08-21 |
Nick Ansari
PRN | Corporate Officer/Principal | 62 | 06-09-22 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Gary Blackford
BRD | Director/Board Member | 66 | 01-01-16 |
Dan Gladney
CHM | Chairman | 70 | 01-11-15 |
Director/Board Member | 70 | 15-06-21 | |
Paul Hickey
CEO | Chief Executive Officer | 59 | 01-02-20 |
Lori McDougal
BRD | Director/Board Member | 62 | 01-07-15 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 0 | 95 388 | 0 | 0 | 88,83 % |
Aandeel B | 1 | 23 457 090 | 20 838 013 ( 88,83 %) | 0 |
Bedrijfsgegevens
Sector
Verkoop per regio
Vaira. 1 jan. | Kapi. | |
---|---|---|
+12,06% | 225 mld. | |
+12,07% | 186 mld. | |
+13,88% | 135 mld. | |
+27,12% | 107 mld. | |
+0,91% | 63,56 mld. | |
+6,74% | 51,32 mld. | |
+13,39% | 51,04 mld. | |
+8,81% | 43,3 mld. | |
+4,14% | 36,99 mld. |